The effect of resveratrol supplementation on C-reactive protein (CRP) in type 2 diabetic patients: Results from a systematic review and meta-analysis of randomized controlled trials

• Published in: Complementary therapies in medicine Vol. 49; p. 102251
• Main Authors: Hosseini, Hossein, Koushki, Mehdi, Khodabandehloo, Hadi, Fathi, Mojtaba, Panahi, Ghodratollah, Teimouri, Maryam, Majidi, Ziba, Meshkani, Reza
• Format: Journal Article
• Language: English
• Published: Scotland Elsevier Ltd 01.03.2020; Elsevier Limited
• Subjects: Bias; Bibliographic data bases; C-reactive protein; Clinical trials; Control methods; CRP; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Evaluation; Hepatocytes; Heterogeneity; Inflammation; Insulin resistance; Maximum likelihood method; Meta-analysis; Performance evaluation; Proteins; Quality; Randomization; Reduction; Resveratrol; Sensitivity analysis; Subgroups; Supplements; Systematic review; Type 2 diabetes; CRP; CVD; Type 2 diabetes; T2DM; RCT; CMA; Resveratrol; SMD; Meta-analysis
• ISSN: 0965-2299; 1873-6963
• DOI: 10.1016/j.ctim.2019.102251

[Display omitted] •CRP plays an important role in the onset and progress of type 2 diabetes.•Meta-analysis was performed using a random-effects model with inverse variance method.•CRP level in T2D patients was reduced following resveratrol supplementation.•Our meta-analysis supports the benefit effects of resveratrol supplementation on CRP. C-reactive protein (CRP) is considered to be an inflammatory marker in type 2 diabetes (T2D) and it is produced by liver cells. The evidence has suggested that resveratrol has anti-inflammatory effect. This study aimed to evaluate the effect of resveratrol supplementation on CRP level in patients with T2D using a systematic review and meta-analysis of randomized controlled trials. Electronic databases were completely searched using Medline, ISI Web of Science, EMBASE and Cochrane Library and Scopus until October 2019. Meta-analysis was performed using random-effects model and inverse variance method. Heterogeneity and publication bias were evaluated in selected studies. Sensitivity analyses and prespecified subgroup were conducted to evaluate potential heterogeneity. Meta-regression was performed to assess the effect of potential confounders on the estimated effect sizes. Six trials comprising a total of 491 subjects were included in this meta-analysis. The results showed significant reduction in the level of CRP [SMD (-0.34 mg/l) (95 % CI, -0.52, to -0.16) p < 0.05] in participants with T2D following supplementation with resveratrol. No significant publication bias was observed in the meta-analysis. Subgroup and sensitivity analyses indicated that the pooled effects of resveratrol supplementation on CRP level in T2D patients were affected by resveratrol dose and duration of resveratrol. Random-effects meta-regression did not indicate any significant association of CRP level with potential confounders including resveratrol dose, duration of treatment, age and gender of type 2 diabetic patients. We found a significant reduction in CRP level in patients with type 2 diabetes, who received resveratrol supplementation.